Annual report pursuant to Section 13 and 15(d)

Equity (Tables)

v3.8.0.1
Equity (Tables)
12 Months Ended
Dec. 31, 2017
Equity [Abstract]  
Schedule of Proceeds from Initial Public Offering

Below is a summary of the gross proceeds to net proceeds calculation.

 

    Shares     $     $
Common Shares                
Base Offering     1,667,000       2,000,400      
Over-Allotment     122,500       147,000      
Gross Proceeds                   2,147,400
Underwriter/Gunnar Expenses                    
Discount             150,318      
Legal Fees             60,000      
Roadshow             1,783      
Miscellaneous             34,005      
Total                   246,106
Akers Biosciences Expenses                    
Legal & Accounting             197,813      
Registration/Regulatory             50,487      
Total                   248,300
Net Proceeds                   1,652,994

 

Below is a summary of the gross proceeds to net proceeds calculation.

 

    Shares     $     $  
Common Shares                        
Base Offering     1,448,400       2,027,760          
Gross Proceeds                     2,027,760  
Underwriter/Gunnar Expenses                        
Discount             141,943          
Legal Fees             50,000          
Total                     191,943  
Akers Biosciences Expenses                        
Legal & Accounting             75,000          
Filing Fees             500          
Total                     75,500  
Net Proceeds                     1,760,317  

 

Below is a summary of the gross proceeds to net proceeds calculation.

    Public Offering - December 21, 2017
    Shares   $   $
Common Shares            
Base Offering     15,500,000       2,325,000          
Over-Allotment     6,000,000       900,000          
Series B Preferred Shares                        
Base Offering     3,675       3,675,000          
Gross Proceeds                     6,900,000  
Underwriter/Gunnar Expenses                        
Discount             483,000          
Non-Accountable Allowance             60,000          
Legal Fees             75,000          
Roadshow             2,558          
Miscellaneous             36,500          
Total                     657,058  
Akers Biosciences Expenses                        
Legal & Accounting             160,000          
Registration/Regulatory             17,356          
Total                     177,356  
Net Proceeds                     6,065,586  

Schedule of Expenses Related to Grants

The expense is included in the Consolidated Statement of Operations and Comprehensive Loss for the year ending December 31, 2017 as follows:

 

Expense Category   2017     2016  
General & Administrative   $ 163,924        
Sales & Marketing     95,770        
    $ 259,694     $